Dr. Sehn Discusses the GAUSS Obinutuzumab Trial

Laurie H. Sehn, MD, MPH
Published: Thursday, Dec 22, 2011

Laurie H. Sehn, MD, MPH, clinical associate professor in the division of medical oncology at the University of British Columbia and the British Columbia Cancer Agency, discusses the phase II randomized GAUSS trial that demonstrated a trend towards a higher objective response rate to obinutuzumab (GA101) compared with rituximab (Rituxan), for patients with indolent non-Hodgkin lymphoma.

Sehn describes the GAUSS trial as the first head-to-head comparison of a novel CD20 monoclonal antibody and rituximab.

Patients in the trial were randomized 1:1 to receive either obinutuzumab or rituximab in 4 weekly induction therapies. Response was assessed following the induction treatment at 24 and 48 days. Patients that did not demonstrate any evidence of disease progression received a maintenance therapy of obinutuzumab or rituximab every 2 months for 2 years.

Laurie H. Sehn, MD, MPH, clinical associate professor in the division of medical oncology at the University of British Columbia and the British Columbia Cancer Agency, discusses the phase II randomized GAUSS trial that demonstrated a trend towards a higher objective response rate to obinutuzumab (GA101) compared with rituximab (Rituxan), for patients with indolent non-Hodgkin lymphoma.

Sehn describes the GAUSS trial as the first head-to-head comparison of a novel CD20 monoclonal antibody and rituximab.

Patients in the trial were randomized 1:1 to receive either obinutuzumab or rituximab in 4 weekly induction therapies. Response was assessed following the induction treatment at 24 and 48 days. Patients that did not demonstrate any evidence of disease progression received a maintenance therapy of obinutuzumab or rituximab every 2 months for 2 years.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x